Emmanouil V Dermitzakis
Overview
Explore the profile of Emmanouil V Dermitzakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Vikelis M, Dermitzakis E, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, et al.
J Clin Med
. 2023 Jul;
12(13).
PMID: 37445560
Objective: this post hoc analysis aimed to evaluate the efficacy of fremanezumab in difficult-to-treat chronic migraine (CM) patients with and without psychiatric comorbidities (PCs), mainly anxiety and/or depression. Methods: We...
12.
Argyriou A, Dermitzakis E, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, et al.
J Clin Med
. 2023 May;
12(9).
PMID: 37176658
Objective: To define, in a real-world population of patients with high-frequency episodic (HFEM) or chronic migraine (CM), the predictive role of socio-demographic or phenotypic profiling of responders to fremanezumab. Patients...
13.
Vikelis M, Argyriou A, Antoniou A, Spingos K, Skliros A, Bilias K, et al.
Medicina (Kaunas)
. 2023 Apr;
59(4).
PMID: 37109692
: Migraine is considered the most clinically important primary headache due to its high prevalence and significant burden. Although globally categorized as one of the leading causes of disability, it...
14.
Argyriou A, Dermitzakis E, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, et al.
Eur J Neurol
. 2023 Feb;
30(5):1435-1442.
PMID: 36773011
Objective: To prospectively assess the efficacy and safety of fremanezumab for migraine prophylaxis in patients with failure of at least three previous preventive treatments. Changes in disability as quality-of-life outcomes...
15.
Papasavva M, Vikelis M, Siokas V, Katsarou M, Dermitzakis E, Raptis A, et al.
Front Neurol
. 2023 Jan;
13:1054333.
PMID: 36698892
Introduction: Migraine is a complex disorder with genetic and environmental inputs. Cumulative evidence implicates oxidative stress (OS) in migraine pathophysiology while genetic variability may influence an individuals' oxidative/antioxidant capacity. Aim...
16.
Dermitzakis E, Kouroudi A, Argyriou A, Spingos K, Bilias K, Vikelis M
Medicina (Kaunas)
. 2023 Jan;
59(1).
PMID: 36676655
The Greek Society of Migraine and Headache Patients conducted, in 2020, its second online survey, titled "Migraine in Greece-2020", after publication of the first similar online survey conducted in 2018....
17.
Argyriou A, Dermitzakis E, Xiromerisiou G, Vikelis M
Toxins (Basel)
. 2022 Dec;
14(12).
PMID: 36548744
We sought to assess the effectiveness of combining dual therapy with onabotulinumtoxinA (BTX) add-on to anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (anti-CGRP MAbs) in treatment-refractory patients with chronic migraine (CM)....
18.
Dermitzakis E, Kouroudi A, Argyriou A, Spingos K, Bilias K, Vikelis M
BMC Neurol
. 2022 Nov;
22(1):440.
PMID: 36411425
The Greek Society of Migraine and Headache Patients (GSMHP), maintaining a strong commitment to research and information, conducted its second web-based online survey named "Migraine in Greece-2020", following its first...
19.
Dermitzakis E, Vikelis M, Vlachos G, Argyriou A
Toxins (Basel)
. 2022 Jul;
14(7).
PMID: 35878172
Background: We aimed to prospectively assess the role of needle length in improving the tolerability/safety profile of OnabotulinumtoxinA (BoNTA) for chronic migraine (CM) prophylaxis, with a specific focus on neck...
20.
Dermitzakis E, Vikelis M, Vlachos G, Argyriou A
Toxins (Basel)
. 2022 May;
14(5).
PMID: 35622543
We aimed to provide insights on the role of the circadian time of administration in influencing the efficacy and tolerability/safety profile of OnabotulinumtoxinA (BoNTA) for chronic migraine (CM) prophylaxis. Methods:...